Business Context and Reporting Period
ARDELYX, INC. filed a Form 8-K on January 8, 2026, reporting preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company is a biopharmaceutical firm focused on gastrointestinal diseases, with primary revenue drivers being IBSRELA and XPHOZAH.
Key Financial Metrics
Revenue
- IBSRELA (tenapanor): Approximately $87 million for Q4 2025 and $274 million for the full year 2025.
- XPHOZAH (tenapanor): Approximately $28 million for Q4 2025 and $104 million for the full year 2025.
- Total U.S. Net Product Sales: Approximately $115 million for Q4 2025 and $378 million for the full year 2025.
Liquidity
- Cash Position: As of December 31, 2025, the Company held approximately $265 million in cash, cash equivalents, and short-term investments.
Other Metrics
The filing does not provide clear values for net profit, operating margins, debt levels, or cash flow from operations.
Material Changes
The filing text does not provide comparative data for the prior year or quarter; therefore, material changes versus the prior comparable period cannot be determined from this document.
Outlook, Risks, and Contingencies
Management Commentary: The reported figures are preliminary and subject to adjustment during the preparation of audited financial statements. Management notes that these amounts may differ materially from the final audited figures.
Audit Status: Ernst & Young LLP has not audited, reviewed, or examined the preliminary data and expresses no opinion on it.
Risks: The primary risk identified is the potential for material variance between these preliminary numbers and the final audited financial statements.
Investor Verification Checklist
- Verify the final audited revenue figures for IBSRELA and XPHOZAH in the upcoming 10-K filing.
- Confirm the final cash, cash equivalents, and short-term investment balance as of December 31, 2025.
- Review the full year 2025 net income and operating cash flow once audited statements are released.
- Assess any adjustments to the preliminary revenue numbers disclosed in the final audit report.